RNAZ.US Transcode Therapeutics Inc

Healthcare Biotechnology USA Stocks
1.35 USD
Close of Nov 17, 2026
1.28 12.60
Market cap
USD 22.9M
P/E
-
P/B
2.83x
ROE
-445.6%
Dividend yield
7,044.87%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is RNAZ.US undervalued?

Graham number

The Graham number of Transcode Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Transcode Therapeutics Inc fundamental analysis

No fundamental analysis for Transcode Therapeutics Inc yet.

Transcode Therapeutics Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Transcode Therapeutics Inc

TransCode Therapeutics, Inc., a clinical-stage company, develops immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers. The company's therapeutic candidate comprises SEVIPROTIMUT-L for the adjuvant treatment of patients with Stages IIB and IIC melanoma that has completed Phase 2 clinical trial; TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colo…

Full company profile